Tcr2 Therapeutics (NASDAQ: TCRR)
Some price data may be temporarily unavailable.
Tcr2 Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tcr2 Therapeutics Company Info
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
News & Analysis
4 Companies That Could Upend the Pharma Industry
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Why TCR2 Therapeutics Is Soaring Today
The company announced positive interim results for one of its experimental treatments.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.